A recent perspective on U.S. health care challenges the conventional view that higher spending leads only to underwhelming health outcomes. The U.S. has been criticized for its healthcare expenditures compared to other high-income countries, with an assumption that rising costs primarily support existing practices rather than improve health results.
However, this view may overlook significant innovations occurring within the health sector. The Bureau of Economic Analysis (BEA) of the Commerce Department has been working to create better metrics for evaluating health system performance. Two new papers from the BEA suggest a need to reconsider the relationship between costs and health outcomes.
Despite higher per capita health costs, the U.S. maintains a unique openness to innovation and technological advancements, which may enhance overall productivity in healthcare. New therapies and intervention techniques are regularly introduced, leading to improved patient health. These factors contribute to discussions on whether increased spending results in notable health improvements or if those improvements are too minimal to influence reforms.
One approach to evaluating this issue involves examining price changes related to the services required for treating specific conditions, adjusting for quality improvements, such as longevity and functional capacity. The authors of the BEA studies pursued this method in their analysis.
The first study by Calvin Ackley, Abe Dunn, and John A. Romley calculated the costs associated with treating Medicare fee-for-service patients experiencing nine common conditions, including heart disease and pneumonia. The authors estimate a 7.5 percent annual productivity improvement from 2002 to 2021 for these conditions, though they acknowledge that other studies report less favorable trends.
A second study by Eli Liebman and the same authors offered a method to assess health sector-wide productivity improvements using data on population health outcomes. They concluded that productivity in U.S. healthcare has been increasing by about 1.0 percent annually, though certain assumptions may significantly alter this estimate.
Notable sources of productivity improvements include new treatments for prevalent conditions like HIV and Hepatitis C, which, despite their initial costs, have led to significant health improvements. Additionally, the expiration of patents for therapies related to conditions like heart disease may facilitate the adoption of more affordable generic options, further enhancing public health outcomes.
However, there are important qualifications to consider. Factors such as improved nutrition and environmental conditions also contribute to population health, complicating the attribution of improved outcomes solely to healthcare services. Furthermore, other countries with strict regulations have reported similar health improvements, suggesting the U.S. might have achieved comparable results without its current innovation-driven model.
Lastly, improvements in specific conditions do not negate the presence of wasteful spending in the overall system. Evidence indicates that excessive pricing in certain services persists due to market distortions, and some patients undergo unnecessary treatments with limited health benefits.
Considering these complexities, there remains significant potential for ongoing productivity improvements in U.S. healthcare, with previous innovations offering a foundation while many opportunities for enhanced efficiency remain unexplored.
Source: www.aei.org via Google News.
